Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.06)
# 2,971
Out of 4,944 analysts
49
Total ratings
37.84%
Success rate
-2.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $31.98 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $46.15 | +108.02% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $8.05 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $63.25 | - | 2 | Jun 10, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $26.87 | - | 2 | Apr 23, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $6.15 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $4.42 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $11.32 | +14.93% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $3.09 | - | 2 | Mar 7, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $57.33 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $85.85 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.61 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.88 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $33.00 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $135.19 | +115.99% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $395.92 | -6.55% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.08 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.86 | - | 1 | May 30, 2017 |
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.98
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $46.15
Upside: +108.02%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $8.05
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $63.25
Upside: -
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $26.87
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.15
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.42
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $11.32
Upside: +14.93%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.09
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $57.33
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $85.85
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.61
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.88
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $135.19
Upside: +115.99%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $395.92
Upside: -6.55%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.08
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.86
Upside: -